Cognex® (tacrine hydrochloride) is a reversible cholinesterase inhibitor, known chemically as 1,2,3,4-tetrahydro-9-acridinamine monohydrochloride monohydrate. Tacrine hydrochloride is commonly referred to in the clinical and pharmacological literature as THA.
Cognex® (tacrine hydrochloride capsules) is indicated for the treatment of mild to moderate dementia of the Alzheimer's type.
Evidence of Cognex®'s effectiveness in the treatment of dementia of the Alzheimer's type derives from results of two adequate and well-controlled clinical investigations that compared tacrine and placebo on both a performance based measure of cognition and a clinician's global assessment of change. (See CLINICAL PHARMACOLOGY Section: Clinical Trial Data).
Published Studies Related to Cognex (Tacrine)
Acute nicotine effects on auditory sensory memory in tacrine-treated and nontreated patients with Alzheimer's disease: an event-related potential study. [2002.05]
The auditory mismatch negativity (MMN) event-related brain potential (ERP) reflects the storage of information in acoustic sensory memory. Thirteen patients with Alzheimer's disease (AD), 6 receiving treatment with the cholinesterase inhibitor, tacrine [tetrahydroaminoacridine (THA)], and 7 receiving no treatment, were administered 2 mg of nicotine polacrilex and placebo.
Safety and efficacy of idebenone versus tacrine in patients with Alzheimer's disease: results of a randomized, double-blind, parallel-group multicenter study. [2002.01]
This study evaluated the safety and efficacy of idebenone vs... We conclude that the benefit-risk ratio is favorable for idebenone compared to tacrine, and furthermore, that this ratio is likely to be similar when comparing idebenone to other cholinesterase inhibitors.
Effects of acute nicotine administration on cognitive event-related potentials in tacrine-treated and non-treated patients with Alzheimer's disease. 
Earlier studies of cognitive event-related brain potentials (ERPs) reporting diminished amplitudes and delayed latencies of the P300 potential in dementia of the Alzheimer type (DAT), together with independent findings of the P300- and performance-enhancing properties of nicotine in normal adults, stimulated this study to explore the single-dose effects of nicotine on auditory and visual P300s in DAT.
Responder characteristics to a single oral dose of cholinesterase inhibitor: a double-blind placebo-controlled study with tacrine in Alzheimer patients. [2001.01]
A proportion of Alzheimer's disease (AD) patients treated for several months with cholinesterase (ChE) inhibitors have shown some favorable response on cognition, but the characteristics of the responders are still unclear. This study attempts to identify the characteristics of individuals with a positive behavioral response after a double-blind randomized administration of a single oral dose of tacrine (40 mg) and placebo to AD patients...
Plasma tacrine concentrations are significantly increased by concomitant hormone replacement therapy. [1999.12]
BACKGROUND: In vitro results suggest that the synthetic hormones used in postmenopausal hormone replacement therapy (HRT) may be significant inhibitors of oxidative drug metabolism. Moreover, HRT has been reported to enhance response to tacrine in postmenopausal patients with Alzheimer's disease, but the mechanism of this interaction remains unclear. OBJECTIVE: To examine the effect of HRT with 2 mg estradiol valerate and 0.25 mg levonorgestrel once daily on the pharmacokinetics of tacrine... CONCLUSIONS: HRT with estradiol and levonorgestrel significantly increased plasma tacrine concentrations. This interaction between tacrine and HRT involves reduced metabolic conversion of tacrine to its main metabolite 1-hydroxytacrine by CYP1A2 during the first-pass phase. The interaction may be clinically important with regard to both enhanced efficacy and increased likelihood of concentration-dependent adverse effects of tacrine in the long-term treatment of patients with Alzheimer's disease. Accordingly, smaller doses of tacrine may be appropriate when coadministered with HRT.
Clinical Trials Related to Cognex (Tacrine)
Tacrine Effects on Cocaine Self-Administration and Pharmacokinetics [Withdrawn]
No medications are currently available for treatment of psychostimulant addiction, a
compulsive preoccupation with use of cocaine and related compounds. Tacrine, a medication
that is currently prescribed for Alzheimer's disease, can decrease the amount of cocaine
injections that laboratory animals choose to inject by vein. This project will determine if
tacrine can also decrease cocaine-motivated behavior for human subjects in a laboratory
Cognition and Exercise Training [Recruiting]
The aim of study is to investigate the impact of two different training modalities (high
intensity interval training (HIIT) versus moderate intensity continuous exercise training
(MICET) on cognitive performance, cerebral oxygenation, cardiac output and physical fitness
in older healthy adults, patients with metabolic syndrome, coronary heart disease and heart
failure. The investigators hypothesized that HIIT modality will lead to a larger
improvement in physical fitness (i. e. VO2peak), cardiovascular parameters (cardiac output
and stroke volume) and cognitive performance at rest and during submaximal exercise. The
primary endpoint will be the improvement in cognitive performance.
Page last updated: 2007-05-02